Senti Bio Awarded $8M CIRM Grant
DENVER, Colo., Jul 01, 2024 (247marketnews.com)- Senti Biosciences, Inc. (Nasdaq:SNTI) stated that it was awarded an $8 million grant from the California Institute for Regenerative Medicines (“CIRM”), which will support its ongoing clinical development of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (“CAR-NK”) investigational cell therapy, for the treatment of relapsed/refractory hematologic malignancies including acute myeloid leukemia (“AML”).
Senti Bio’s Chief Executive Officer and Co-Founder, Timothy Lu, M.D., Ph.D., stated, “On behalf of the Senti Bio team, I’d like to express our sincere gratitude to CIRM for its support of our Phase 1 trial of SENTI-202 and for recognizing SENTI-202’s potential to improve the lives of people living with AML.
“We are proud of the clinical development progress to date as the Phase 1 trial continues to enroll and will remain steadfast in our mission to provide potentially lifesaving treatments for people living with cancer.”
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com
Related news for (SNTI)
- Breaking News: MoBot’s Latest Update as of 07/14/25 05:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/14/25 04:00 AM
- Don’t Miss Out: MoBot’s Latest Stock Updates 07/11/25 07:00 PM
- Senti Biosciences Announces New Employment Inducement Grants
- Senti Biosciences Announces New Employment Inducement Grants